All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.
Long-lasting responses were observed following treatment with BXCL701 plus pembrolizumab (Keytruda) for patients with platinum-resistant, small-cell neuroendocrine prostate cancer, according to results from a phase 2a trial (NCT03910660).
The composite and RECIST response rates were 25% and 20%, respectively among patients treated with the combination; the latter included 4 confirmed partial responses (PR) and 1 unconfirmed PR. Moreover, the disease control rate was 48% with a circulating tumor cell (CTC) response rate of 25%.
The results were presented at the 2023 Genitourinary Cancers Symposium.
Patients were given 200 mg of pembrolizumab intravenously every 3 weeks on day 1 plus BXCL701 at 0.3 mg by mouth twice a day on days 1 to 14 during each 21-day cycle. During cycle 1 step-up dosing was permitted with BXCL701 given at 0.2 mg by mouth twice a day on days 1 to 7 followed by 0.3 mg by twice daily on days 8 to 14.
The primary end points included composite response rate, objective response by RECIST 1.1. criteria, and/or circulating tumor cell conversion from less than 5/7.5 mL or more to less than 5/7.5 mL and/or a 50% or higher prostate-specific antigen decrease from baseline. Secondary end points included duration of response (DOR), progression-free survival, changes in circulating cytokines, and correlations of outcomes with baseline tumor characteristics.
A total of 34 patients were included in the phase 2a portion of the study. The median patient age was 67.5 years old (range, 54-80). A majority of patients had an ECOG performance status of 0 or 1 (47%), respectively. Additionally, visceral metastases were most often present at any site (62%) while fewer patients had liver metastases (32%). Patients had a median of 3 prior lines of therapy.Prior systemic therapies included androgen signaling inhibitors (89%), platinum-based chemotherapy (68%), and taxane chemotherapy (50%).
To be enrolled in the trial, patients were required to have confirmed de novo small-cell neuroendocrine cancer, received 1 or more prior lines of therapy, and have progressive disease. Additionally, they needed to have serum testosterone of less than 50 ng/dL during screening except for those with de novo disease, and an ECOG performance status of 0 to 2.
Exclusion criteria included having had more than 2 cytotoxic chemotherapy regimens for metastatic castration-resistant prostate cancer, or prior treatment with an anti–PD-1, anti–PD-L1, or anti–PD-L2 agent or an agent with another co-inhibitory T-cell receptor.
The median duration of follow-up was 30.8 weeks (range, 1.9-86.9), and the median duration of treatment was 9 weeks (range, 0.7-73.0). Investigators noted that there were 28 evaluable patients as of December 19, 2022.
The median DOR by composite and RECIST criteria was over 6 months (range, 1.3-17.4; range, 1.8-9.8), respectively.
In the evaluable patient population, all responders were microsatellite stable and/or tumor mutational burden low.
Grade 3 treatment-emergent adverse effects (TEAEs) occurred in 47% of patients and 3% had grade 5 events. AEs that led to discontinuation occurred in 18% of patients, with 18% attributed to BXCL701 and 15% to pembrolizumab. Additionally, immune-related AEs occurred in 41% of patients, 7% of which were grade 3 or higher.
Common any-grade TRAEs included fatigue, hypotension, pruritus, dizziness, and nausea.
Aggarwal RR, Zhang J, Monk P, et al. First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: phase 2a final results. J Clin Oncol. 2023;41(suppl):176. doi:10.1200/JCO.2023.41.6_suppl.176
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.